Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 4195: MIR002: a new POLA1 inhibitor endowed with a large spectrum of antitumor activity

Claudio Pisano, Lucio Merlini, Sergio Penco, Raffaella Cincinelli, Nadine Darwiche, Mario B. Guglielmi, Antonietta Esposito, Ilaria La Porta, Giacomo Signorino, Gabriele De Rubis, Fabiana Colelli, Francesco Cardile, Alessandra Fucci, Egildo L. D'Andrea and Sabrina Dallavalle
Claudio Pisano
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucio Merlini
University of Milan, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Penco
Ronzoni Institute for Chemical and Biochem Research, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raffaella Cincinelli
University of Milan, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Darwiche
American University of Beirut, Beirut, Lebanon;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario B. Guglielmi
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonietta Esposito
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilaria La Porta
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giacomo Signorino
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriele De Rubis
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiana Colelli
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Cardile
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Fucci
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egildo L. D'Andrea
Biogem, Centro Ricerche, Ariano Irpino (AV), Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Dallavalle
Univesity of Milan, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-4195 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

A recent work from Han et al. disclosed DNA polymerase 1 alpha (POLA1) as the key target for the anti-cancer effects of CD437, a molecule belonging to the class of Retinoid Related Molecules (RRMs). Before this evidence, this family of compounds, of which CD437 and ST1926 represent the prototypes, has been characterized for its antiproliferative, antitumor and pro-apoptotic activity. With aim to identify a new RRM with an improved pharmacological profile, we recently selected MIR002 as a novel compound endowed with a potent antitumor activity and a peculiar pharmacological profile. In vitro treatment with MIR002 leads to a G1/S arrest and exerts a potent anti-tumor/proapoptotic activity in a wide range of cancer cell lines, including H460-R9A cells, which are cross resistant to ST1926 and CD437 (IC50>70 fold of H460-R9A vs H460). Moreover, in H460-R9A cells, we identified the L764F mutation in POLA1, already described as a mutation conferring resistance to CD437. We also demonstrated that POLA1 is the molecular target of both MIR002 and ST1926 and that, interestingly, the expression of the L764F mutant, although associated with the resistance to RRM’s, only marginally reduces the cytotoxic effects of MIR002. In order to investigate the activity of MIR002 against tumor growth, we examined a panel of in vivo xenograft tumor models, including those originating from human Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM). In these models, using a q2dx5x3w schedule in doses ranging from 50 to 70 mg/Kg administered orally, we observed a strong tumor growth inhibition (TGI>70%). Interestingly, the combination of MIR002 with Cisplatin (4mg/Kg; qd7x3w; i.v.) in MPM models showed a synergistic antitumor efficacy, reaching a TGI>90%, and cured animals. Interestingly, we previously identified POLA1 as a key pro-proliferative player in 9 primary MPM samples. The ex-vivo analyses indicated that POLA1 expression was strongly modulated upon MIR002 treatment. Furthermore, in the same models, we also observed that the expression/secretion of multiple circulating factors is affected by MIR002 and we identified some of them as potential biomarkers of tumor responsiveness to MIR002. Taken together, our results identify MIR002 as a novel anti-cancer compound and suggest POLA1 as a target for new antitumor strategies to be investigated in Clinical Trials.

Citation Format: Claudio Pisano, Lucio Merlini, Sergio Penco, Raffaella Cincinelli, Nadine Darwiche, Mario B. Guglielmi, Antonietta Esposito, Ilaria La Porta, Giacomo Signorino, Gabriele De Rubis, Fabiana Colelli, Francesco Cardile, Alessandra Fucci, Egildo L. D'Andrea, Sabrina Dallavalle. MIR002: a new POLA1 inhibitor endowed with a large spectrum of antitumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4195. doi:10.1158/1538-7445.AM2017-4195

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 4195: MIR002: a new POLA1 inhibitor endowed with a large spectrum of antitumor activity
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 4195: MIR002: a new POLA1 inhibitor endowed with a large spectrum of antitumor activity
Claudio Pisano, Lucio Merlini, Sergio Penco, Raffaella Cincinelli, Nadine Darwiche, Mario B. Guglielmi, Antonietta Esposito, Ilaria La Porta, Giacomo Signorino, Gabriele De Rubis, Fabiana Colelli, Francesco Cardile, Alessandra Fucci, Egildo L. D'Andrea and Sabrina Dallavalle
Cancer Res July 1 2017 (77) (13 Supplement) 4195; DOI: 10.1158/1538-7445.AM2017-4195

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 4195: MIR002: a new POLA1 inhibitor endowed with a large spectrum of antitumor activity
Claudio Pisano, Lucio Merlini, Sergio Penco, Raffaella Cincinelli, Nadine Darwiche, Mario B. Guglielmi, Antonietta Esposito, Ilaria La Porta, Giacomo Signorino, Gabriele De Rubis, Fabiana Colelli, Francesco Cardile, Alessandra Fucci, Egildo L. D'Andrea and Sabrina Dallavalle
Cancer Res July 1 2017 (77) (13 Supplement) 4195; DOI: 10.1158/1538-7445.AM2017-4195
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Targeting Protein Kinases and DNA Repair

  • Abstract 4201: Combination of palbociclib with enzalutamide shows in vitro activity in RB-proficient and androgen receptor-positive triple-negative breast cancer cells
  • Abstract 4196: Anti-tumor activity of a TAM kinase-targeting compound in CT-26 syngeneic mouse model
  • Abstract 4181: Discovery of a selective small molecule inhibitor of Tankyrase by structure-based screening
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement